Method for detection of a neurological disease

A neurological disease, disease technology, applied in disease diagnosis, biological testing, measurement devices, etc., can solve problems such as expensive

Inactive Publication Date: 2014-05-28
COMMONWEALTH SCI & IND RES ORG +3
View PDF11 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these kits use expensive instruments such as mass spectrometers and in some cases require the use of CSF

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detection of a neurological disease
  • Method for detection of a neurological disease
  • Method for detection of a neurological disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0228] 1. Sample Collection and Analysis

[0229] 1.1 Dataset

[0230] Two datasets are used. The first set was obtained from the Australian Imaging, Biomarkers, and Lifestyles (AIBL) Study. Details on the study design and registration procedures have been discussed (Ellis et al., 2009). The cohort consisted of 1090 subjects (207 with clinically established Alzheimer's disease (AD), 129 had mild cognitive impairment (MCI) and 754 were healthy controls (HC). 273 subjects underwent both blood measurements and imaging (PiB-PET). Over an 18-month time frame, acquisition PET images and samples are obtained for blood measurements, however blood measurements are yet to be determined.

[0231] The second set was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http: / / www.loni.ucla.edu / ADNI). Each of these samples had baseline blood measurements and PET imaging at baseline or twelve-month follow-up. Information on ADNI studies has been detailed (M...

example 2

[0281] 1.1 Dataset

[0282] The same samples from the AIBL cohort discussed in Example 1 as well as ADNI were used for this second round of analysis.

[0283] Certain markers, as used in Example 1, are presented here in consideration of the difficulties that may be encountered when using certain markers in a clinical setting—difficulties due to their assay measurement being potentially unreliable, tricky to perform, or too variable. ignored in the second round of analysis. Instead, four other biomarkers of interest, demographic and clinical, were appended to the blood analytes; included markers were gender, ApoE ε4 carrier status, years of education, and CDR pen box.

[0284] The demographic composition of the two imaging (AIBL and ADNI) datasets split by high and low NAB for these four markers, age, and clinical class (HC, MCI, or AD) is given in Table 4. Demographic differences between high and low NAB were assessed using χ2 tests against categorical variables, and analy...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The present invention provides methods for predicting whether a subject will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the predictive detection of neurological diseases in a subject. The methods and systems provided enable a quantitative assessment and theoretical predictions of neocortical amyloid loading or amyloid beta levels based on the measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD).

Description

field of invention [0001] The present invention relates to methods for predicting the prognosis of neurological diseases affecting cognitive function. More specifically, the present invention relates to the detection of prognosis in a subject of a neurological disease associated with elevated amyloid burden, such as Alzheimer's disease. Background of the invention [0002] Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory loss and leads to progressive loss of cognitive function and dementia, affecting one in eight people by the age of 65. Neuropathologically, AD is characterized by the presence of neuritic plaques (NPs), neurofibrillary tangles (NFTs), and loss of neurons, along with a variety of other findings. [0003] AD can strike people as young as 40 to 50 years old, however the timing of onset is generally unknown because the presence of the disease is difficult to determine without invasive techniques such as brain biopsies. In practic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/96G16B25/00
CPCG01N2333/4709G01N33/6896G01N2800/2821G01N2800/60G06F19/20G16B25/00
Inventor 萨曼莎·C·伯纳姆诺埃尔·福克斯西蒙·M·劳斯
Owner COMMONWEALTH SCI & IND RES ORG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap